Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Hematology/Oncology Clinics of North America|April 6, 2023
Targeted Therapy for Non-Small Cell Lung Cancer: First Line and BeyondElliott Brea, Julia Rotow
Nature Reviews. Cancer|October 26, 2017
Understanding and targeting resistance mechanisms in NSCLCJulia Rotow, Trever G Bivona
Pharmacological Reviews|October 5, 2013
Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancerBenjamin Izar, Julia Rotow, Justin Gainor, et al.
Clinical and Translational Science|July 2, 2010
Vaccines as monotherapy and in combination therapy for prostate cancerJulia Rotow, Sofia R Gameiro, Ravi A Madan, et al.
Lung Cancer (Amsterdam, Netherlands)|October 19, 2025
Outcomes with neoadjuvant osimertinib and/or chemotherapy in patients with EGFR-mutant resectable non-small cell lung cancersPrashasti Agrawal, Julia Rotow, Gaetano Rocco, et al.
The Oncologist|July 1, 2025
Mitigation and management of adverse events associated with amivantamab therapyNarjust Florez, Nicole R LeBoeuf, Julia Rotow, et al.
Frontiers in Oncology|February 7, 2024
Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus reportMyriam Mirza, Aseem Shrivastava, Cecile Matthews, et al.
The Oncologist|May 18, 2024
The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLCAllison E B Chang, Andrew J Piper-Vallillo, Raymond H Mak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2023
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung CancersJulia Rotow, Jyoti D Patel, Matthew P Hanley, et al.
JCO Precision Oncology|November 16, 2023
Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to SelpercatinibMalini M Gandhi, Biagio Ricciuti, Guilherme Harada, et al.
Pageof 2